Tags : Venclexta/Venclyxto

Roche Reports Results of Venclexta/Venclyxto (venetoclax) in P-III CLL14 Study

Vartika Singh June 5, 2019

Shots: The P-III CLL14 Study involves assessing of Venclexta/Venclyxto + Gazyva/Gazyvar vs Gazyva/Gazyvaro + chlorambucil in 432 patients with previously untreated chronic lymphocytic leukemia (CLL) P-III CLL14 Study results: ORR […]readmore

Regulatory

AbbVie Reports FDA’s Hold on All Clinical Trials Evaluating Venclexta/Venclyxto

Tuba Khan March 20, 2019

Shots: The partial clinical hold follows P-III BELLINI trial (M14-031)study results assessing Venetoclax + bortezomib + dexamethasone vs PBO + bortezomib + dexamethasone in patients with 1L+ r/r multiple myeloma […]readmore

Tags : Venclexta/Venclyxto

Roche Reports Results of Venclexta/Venclyxto (venetoclax) in P-III CLL14 Study

AbbVie Reports FDA’s Hold on All Clinical Trials Evaluating Venclexta/Venclyxto

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Venclexta/Venclyxto

Roche Reports Results of Venclexta/Venclyxto (venetoclax) in P-III CLL14 Study

AbbVie Reports FDA’s Hold on All Clinical Trials Evaluating Venclexta/Venclyxto

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company